Introduction: Patients with major depressive disorder (MDD) often fail to respto first-line
other drug. The objective of this prospective, case review study was to identify factors that influence the decision to prescribe adjunctive antipsychotics for patients with MDD and inadequate response to ADT.
Methods:
Psychiatrists or primary care physicians (n = 411) based in the USA and Europe each completed an online survey for ten consecutive adults with MDD and inadequate response to ADTs, and for whom a treatment change was considered. A t test was used to compare survey responses between groups of patients.
Results:
The survey was completed for 4018 patients; an adjunctive antipsychotic was considered for 961/4018 patients (23.9%) and actually prescribed for 514/4018 (12.8%). Compared with patients not considered for an adjunctive antipsychotic, those who were considered for this treatment had more previous major depressive episodes (MDEs), longer duration of the current MDE, more severe illness both at ADT initiation and current consultation, and more treatment changes. Patients who were prescribed adjunctive antipsychotics had at baseline more functional impairment and absences from work than those considered for but not prescribed this treatment. Key symptoms that prompted physicians to consider antipsychotics were psychotic symptoms, psychomotor agitation, hostility, irritability, impulsivity, and anger bursts. Anxious mood and irritability were mentioned significantly more often by physicians who actually prescribed adjunctive antipsychotics.
Obstacles to prescribing included a tendency to wait to see if symptoms improved and concern over side effects.
INTRODUCTION
Despite the availability of a range of antidepressant treatments (ADTs), many patients with major depressive disorder (MDD) only have a partial response to first-line therapies [1, 2] . An inadequate response is more likely to occur in patients with a longer duration of illness, more severe symptoms and comorbid illnesses [3] . Since incomplete remission is associated with an increased risk of relapse, impaired work and social functioning, and an increased risk of suicide antipsychotic [1, 4, 5] which has been shown to improve the clinical response rate at 6 weeks in patients with MDD refractory to ADT by as much as 50% [6] . However, second-generation antipsychotics are frequently associated with intolerable side effects [7, 8] .
With increasing numbers of both ADTs and second-generation antipsychotics indicated for use in MDD, the absence of evidence-based guidelines and lack of high-quality data [9] complicates the choice of adjunctive drug for patients with an inadequate response to monotherapy. The choice of treatment for any individual patient may depend on factors such as symptomatology, disease and treatment history, and patient preference. A retrospective study on choice of adjunctive treatment reported that augmentation of ADT with a second-generation antipsychotic was more likely in patients with the most severe depression [10] .
The objective of this case review study was to examine real-world data from patient records to identify the key factors that influence the treatment decision for patients with MDD and an inadequate response to ADT.
METHODS

Study Design
This chart review study was designed to be 
RESULTS
Physicians
The survey was completed by 411 physicians located in the USA (129, 31.4%), France (58, 14.1%), UK (57, 13.9%), Italy (56, 13.6%), Spain In a typical month, they saw an average of 98 adults with MDD, around half of whom (47) were inadequately responding to ADT. On average, physicians estimated that 81.9% of their patients with MDD were receiving treatment for an acute episode, comprising 41.1% who were responding adequately, 19 .8% with some unresolved symptoms but not requiring a change to their treatment regimen, and 21.0% with an inadequate response that did require a treatment change. The remaining patients (18.1%) were receiving maintenance therapy to prevent further relapse.
Treatments
Physicians completed the survey for a total of 4018 patients whom they identified as having MDD and an inadequate response to current treatment. Prior to the current consultation, 1880/4018 patients (46.8%) were receiving monotherapy, mostly with an ADT (1766/ 4018, 44.0%), and 2137/4018 patients (53.2%) were on combination therapy (see Table 1 ). The combinations most frequently mentioned were an ADT with a benzodiazepine (492/4018, 12.2%) or an ADT with an antipsychotic (294/ 4018, 7.3%). Other combinations (860/4018, 21.4%) comprised various combinations of three or more drugs. Antipsychotics were being prescribed to 40/4018 patients (1.0%) as monotherapy and 294/4018 (7.3%) as an adjunctive to an ADT.
At the current consultation, physicians were most likely to switch the ADT to a different drug or add a new adjunctive drug (see Table 2 ). A treatment change involving an adjunctive antipsychotic was considered for 961/4018 patients (23.9%). Around half of these patients were actually prescribed an adjunctive antipsychotic (514/4018, 12.8%). This was prescribed as a new adjunctive drug for 343/4018 patients (8.5%) and as a switch of an existing adjunctive drug for 173/4018 patients (4.3%). Two patients were each prescribed two new adjunctive antipsychotics and one patient was prescribed a new adjunctive antipsychotic and was switched from a currently prescribed drug to an antipsychotic. In addition, antipsychotic monotherapy was newly prescribed for 55/4018 patients (1.4%).
Physicians appeared to be more likely to consider prescribing or actually prescribe adjunctive antipsychotics for patients who were already on combination therapy than those on monotherapy (see Table 1 ).
When considering the influence of physician experience on this treatment decision, experienced physicians ([15 years in practice, based on median experience) prescribed adjunctive antipsychotics in 242/1779 (13.6%) patients compared with 272/2239 (12.2%) patients prescribed adjunctive antipsychotics 
Patient Demographics and Disease History
The study population was spread across all age categories from 18-24 years to C65 years (see Table 3 ). Slightly more than half of the patients were female. Compared with patients who were not considered for an adjunctive antipsychotic, there was some evidence that those who were considered for or prescribed this treatment had more previous MDEs, longer duration of the current MDE, greater CGI-S score both at ADT initiation and the current consultation, and more previous treatment changes (see Table 3 ). (prescribed: n = 376, mean 17.4 days/month versus considered: n = 317, mean 13.9 days/ month; P\0.05).
Physicians considered MDD to have a great impact on family relationships in a significantly larger proportion of patients prescribed (n = 514) 
Factors Influencing Prescription of an Adjunctive Antipsychotic
The most common reason given by physicians for the actual prescription of an adjunctive antipsychotic was better efficacy or symptom control (52%, Fig. 1 ). Specific drug features that were mentioned included non-sedative calming (20%), sedation (16%), and activation (14%). When physicians were asked to identify their top three influences on the treatment decision, the highest ranked factors overall were their familiarity with or trust in the drug, the patient's level of functioning, a better tolerability profile, and the patient's history of MDD.
The most common reason that physicians gave for not prescribing an adjunctive antipsychotic or for not prescribing this treatment earlier was a preference to wait to see if the symptoms improved (1010/3538, Fig. 1 Physician's reasons for deciding to prescribe an adjunctive antipsychotic. Drugs prescribed: aripiprazole (n = 174), quetiapine XR (n = 103), quetiapine IR (n = 96), olanzapine (n = 57), risperidone (n = 52), other antipsychotic (n = 22), lurasidone (n = 12), iloperidone (n = 1). Number of patients = 514; total number of drugs prescribed = 517, two patients were each prescribed two new adjunctive antipsychotics and one patient was prescribed a new adjunctive antipsychotic and was switched from a currently prescribed drug to an antipsychotic 28.6%, based on the number of responses; Fig. 2 Fig. 3 ). These symptoms were relatively consistently selected across regions: US physicians identified their top symptoms as Fig. 2 Physician's reasons for not prescribing an adjunctive antipsychotic in patients who were not considered for this treatment and those who were considered but not prescribed this treatment, and for not prescribing earlier in those who were prescribed this treatment. Number of responses = 3538, comprising data for 2577 patients who
were not considered for an adjunctive antipsychotic, 447 patients who were considered for but not prescribed this treatment, and 514 patients who were prescribed this treatment (i.e., reasons for not prescribing earlier). ADT antidepressant treatment, AP antipsychotic, DDI drugdrug interaction, MDD major depressive disorder Augmentation or combination strategies are recommended by treatment guidelines for patients with MDD who experience partial or no response to ADT [11] . Among strategies to augment response with non-ADTs, adjunctive second-generation antipsychotics are supported by the strongest evidence [1] . In this study, a treatment change involving an adjunctive antipsychotic was considered for 23.9% of the retrospective study using data from patient records reported that patients with severe depression had an increased likelihood of augmentation with second-generation antipsychotics [10] . In our study, functional impairment was also associated with adjunctive antipsychotic prescribing. Although employment status was similar in patients who were considered for and prescribed adjunctive antipsychotics, it is interesting that the patients who were actually prescribed this treatment tended to take more days off work and to experience more time during which they were unable to perform their daily tasks at the usual level. It is noteworthy that physicians considered MDD to have a great impact on family relationships, social relationships and involvement in hobbies, interests and voluntary work, in more than half of the patients who were prescribed adjunctive antipsychotics, providing further evidence that functional impairment guides the treatment decision process.
The most common reason given by the physicians for adjunctive antipsychotic prescribing was to achieve better efficacy or control of symptoms. Physicians who stated that they reserved antipsychotics for patients with specific symptoms indicated that key triggers would be psychotic symptoms, and arousal symptoms such as psychomotor agitation, hostility, irritability, impulsivity, and anger bursts. That those physicians who reserved antipsychotic treatment were triggered to add an antipsychotic by presence of psychotic symptoms is perhaps not surprising, but does raise the possibility that this is uncovering the well-documented underdiagnosis of bipolar spectrum disorder by these physicians [12] . Anxious mood and irritability were more likely to be mentioned as trigger symptoms by physicians who actually prescribed adjunctive antipsychotics to survey patients than those who did not prescribe. For the patients included in this survey, unsurprisingly, moderate-to-severe depression was a key influence on the treatment decision; interestingly, moderate-to-severe anxiety was also an important factor that led the physician to consider adjunctive antipsychotics. It is recognized that anxiety symptoms are common in patients with MDD [13, 14] and are associated with greater illness severity, unfavorable course of illness, impaired functioning, and poorer health-related quality of life [15] [16] [17] 
